Milestone Pharmaceuticals Stock (NASDAQ:MIST)

Forecast Ownership Financials Chart

Previous Close

$1.57

52W Range

$0.63 - $2.75

50D Avg

$1.68

200D Avg

$1.69

Market Cap

$134.24M

Avg Vol (3M)

$1.50M

Beta

0.96

Div Yield

MIST Company Profile

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

May 09, 2019

Website

MIST Performance

MIST Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	$1.00M	$5.00M
Operating Income	$-42.10M	$-61.10M	$-59.64M
Net Income	-	$-59.69M	$-57.13M
EBITDA	$-42.10M	$-56.84M	$-58.36M
Basic EPS	$-0.67	$-1.39	$-1.35
Diluted EPS	$-0.67	$-1.39	$-1.35

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
KZR	Kezar Life Sciences, Inc.
SCPH	scPharmaceuticals Inc.
NXTC	NextCure, Inc.
VRNA	Verona Pharma plc
LYRA	Lyra Therapeutics, Inc.
DMAC	DiaMedica Therapeutics Inc.
IMRN	Immuron Limited
CNTA	Centessa Pharmaceuticals plc
ATYR	aTyr Pharma, Inc.